160 related articles for article (PubMed ID: 29181687)
41. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
42. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies.
Chen H; Lin J; Shan Y; Zhengmao L
Biomed Pharmacother; 2019 Jul; 115():108857. PubMed ID: 31048191
[TBL] [Abstract][Full Text] [Related]
43. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
44. All-trans retinoic acid-loaded lipid nanoparticles as a transdermal drug delivery carrier.
Charoenputtakhun P; Opanasopit P; Rojanarata T; Ngawhirunpat T
Pharm Dev Technol; 2014 Mar; 19(2):164-72. PubMed ID: 23356887
[TBL] [Abstract][Full Text] [Related]
45. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth.
Nguyen PH; Giraud J; Staedel C; Chambonnier L; Dubus P; Chevret E; Bœuf H; Gauthereau X; Rousseau B; Fevre M; Soubeyran I; Belleannée G; Evrard S; Collet D; Mégraud F; Varon C
Oncogene; 2016 Oct; 35(43):5619-5628. PubMed ID: 27157616
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib-Loaded Ligand-Functionalized Polymer-Lipid Hybrid Nanoparticles for Enhanced Therapeutic Effect Against Liver Cancer.
Tang S; Li Y
J Nanosci Nanotechnol; 2019 Nov; 19(11):6866-6871. PubMed ID: 31039838
[TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles.
Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J
Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790
[TBL] [Abstract][Full Text] [Related]
48. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
49. Effects of retinoic acid on metastasis and its related proteins in gastric cancer cells in vivo and in vitro.
Wu Q; Chen YQ; Chen ZM; Chen F; Su WJ
Acta Pharmacol Sin; 2002 Sep; 23(9):835-41. PubMed ID: 12230954
[TBL] [Abstract][Full Text] [Related]
50. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
[TBL] [Abstract][Full Text] [Related]
51. Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo.
Wang YR; Yang SY; Chen GX; Wei P
Biochem Biophys Res Commun; 2018 Apr; 499(1):8-16. PubMed ID: 29534962
[TBL] [Abstract][Full Text] [Related]
52. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders.
Lim SJ; Lee MK; Kim CK
J Control Release; 2004 Nov; 100(1):53-61. PubMed ID: 15491810
[TBL] [Abstract][Full Text] [Related]
53. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Huo ZJ; Wang SJ; Wang ZQ; Zuo WS; Liu P; Pang B; Liu K
Cancer Sci; 2015 Oct; 106(10):1429-37. PubMed ID: 26177628
[TBL] [Abstract][Full Text] [Related]
54. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
55. Anti-metastatic study of liposome-encapsulated all trans retinoic acid (ATRA) in B16F10 melanoma cells-implanted C57BL/6 mice.
Siddikuzzaman ; Grace VM
Cancer Invest; 2014 Dec; 32(10):507-17. PubMed ID: 25311249
[TBL] [Abstract][Full Text] [Related]
56. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2].
Lu HQ; Zheng J
Ai Zheng; 2006 Dec; 25(12):1470-6. PubMed ID: 17166369
[TBL] [Abstract][Full Text] [Related]
57. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
58. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Riedel M; Struve N; Müller-Goebel J; Köcher S; Petersen C; Dikomey E; Rothkamm K; Kriegs M
Oncotarget; 2016 Sep; 7(38):61988-61995. PubMed ID: 27542273
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
60. Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and Paclitaxel based on hyaluronic acid-based multifunctional nanocarrier.
Yao J; Zhang L; Zhou J; Liu H; Zhang Q
Mol Pharm; 2013 Mar; 10(3):1080-91. PubMed ID: 23320642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
